Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Adaptimmune Therapeutics Stock Is Spiking Today

TheMotleyFool

0 0

Why Adaptimmune Therapeutics Stock Is Spiking TodayPhoto, wide shot, wide-angle lens, Medical device manufacturer, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/3a7f6312-1eee-4702-9005-93cc1e62f970.png

Adaptimmune Therapeutics (NASDAQ: ADAP), a clinical-stage biotech, saw its shares spike by as much as 10% in early morning trading Monday. Although the stock has cooled off somewhat in afternoon trading, its shares were still up by a healthy 8% as of 12:52 p.m. EDT Monday.

Adaptimmune's stock appears to be moving northward today in response to Pfizer's $2.26 billion buyout of oncology specialist Trillium Therapeutics. In short, investors are apparently on the hunt for the next buyout play in oncology.

Image source: Getty Images.

Source Fool.com

Like: 0

ADAP

Share